Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Merrill D. Benson(Indiana University School of Medicine), Teresa Coelho(Universidade do Porto), Bradley McEvoy(Université Paris-Sud), Stephen B. Heitner(Brigham and Women's Hospital), Morie A. Gertz(Medical University of South Carolina), Giuseppe Vita(University of Messina), Peter D. Gorevic(Université Paris-Sud), John L. Berk(Boston University), Hartmut Schmidt(Université Paris-Sud), Márcia Waddington‐Cruz(Université Paris-Sud), William J. Litchy(Mayo Clinic), Annabel K. Wang(Université Paris-Sud), Amil M. Shah(Brigham and Women's Hospital), Brenda F. Baker(Ionis Pharmaceuticals (United States)), Josep M. Campistol(Universitat de Barcelona), Violaine Planté‐Bordeneuve(Université Paris-Est Créteil), Brett P. Monia(Ionis Pharmaceuticals (United States)), Fábio Barroso(Université Paris-Sud), Scott D. Solomon(Brigham and Women's Hospital), Carol Whelan(The Royal Free Hospital), Thomas H. Brannagan(Columbia University), Isabel Conceição(Université Paris-Sud), Brian Drachman(British Heart Foundation), Laura Obici(University of Pavia), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Michael Polydefkis(Université Paris-Sud), Josep Gámez(Université Paris-Sud), Giampaolo Merlini(University of Pavia), Morton Scheinberg(Université Paris-Sud), Edward Gane(University of Auckland), David Adams(Mount Sinai Health System), Elizabeth J. Ackermann(Université Paris-Sud), P. James B. Dyck(Mayo Clinic), Shiangtung W. Jung(Université Paris-Sud), T. Jesse Kwoh(Université Paris-Sud)
New England Journal of Medicine
July 4, 2018
Cited by 1,420


Related Papers